Pharma Pulse 3/6/25: Legal and Political Implications of NIH Funding Freeze, Advances in Cancer Care from Pets to Humans & more

Legal and Political Implications of the NIH Funding Freeze

Ron Lanton, Partner, Lanton Law, shares his insights on the legal and political consequences of the NIH funding freeze and potential options for continuing research.

Comparative Oncology: Advances in Cancer Care from Pets to Humans

Dogs share a number of cancers with humans, including melanoma, non-Hodgkin lymphoma, leukemia, and osteosarcoma.

AI Drug Firm Recursion Wants to Be Amazon Prime of Pharma

AI drug developer Recursion Pharmaceuticals Inc. is considering an Amazon Prime-style subscription model for selling its pipeline of medicines.

MedaSystems Secures Additional Seed Financing to Advance Its AI-Driven Workflow Platform for Expanded Access and Investigator-Initiated Studies

MedaSystems announced additional funding from existing investors, Debiopharm Innovation Fund, Nina Capital, and Young Sohn, a co-founder of Veeva Systems. This investment underscores confidence in MedaSystems’ ability to modernize pre-approval access pathways through its AI-driven workflow platform. By streamlining Expanded Access and IIS workflows, MedaSystems helps pharmaceutical companies and healthcare providers efficiently manage requests, improve patient access, and capture real-world data to support evidence generation and regulatory submissions.

Russo Partners on LinkedIn

2024 saw record-high biotech M&A deal values and a surge in equity offerings. With strategic partnerships and acquisitions on the rise, the industry is poised for further growth in 2025.

Read more in Pharmaceutical Executive : https://bit.ly/3Xm1Vm7

#Biotech #Pharma #M&A #MergersAndAcquisitions

Have news you want us to share in Pharma Pulse? Reach out to Editor Miranda Schmalfuhs